Hyong Kim
CIK 1993255 · Chief Medical Officer · last filed 2026-10-07
Hyong Kim is a Chief Medical Officer who has filed 38 SEC Form 4 insider transactions across 1 company since 2023. The most recent filing shows the insider sold $269.6K of ALHC on Oct 7, 2026. Across all open-market trades the lifetime net is −$6.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALHC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1100 W TOWN AND COUNTRY ROAD, SUITE 1600
ORANGE, CA 92868
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALHC | Chief Medical Officer | 299,271 | $7.04 | $2.11M | -$6.62M | 20 | 2026-10-07 |
Recent Filings
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-07 | ALHC | Sell (S) | −32,479 | -$269.6K | EDGAR |
| 2026-10-05 | ALHC | Notice (144) | −36,000 | -$305.3K | EDGAR |
| 2026-06-15 | ALHC | Sell (S) | −35,951 | -$713.9K | EDGAR |
| 2026-06-12 | ALHC | Notice (144) | −35,951 | -$727.6K | EDGAR |
| 2026-03-19 | ALHC | Sell (S) | −18,404 | -$328.3K | EDGAR |
| 2026-03-17 | ALHC | Grant (A) | +52,972 | $0 | EDGAR |
| 2026-03-16 | ALHC | Notice (144) | −38,762 | -$658.6K | EDGAR |
| 2026-01-06 | ALHC | Notice (144) | −16,506 | -$346.6K | EDGAR |
| 2026-01-06 | ALHC | Sell (S) | −16,506 | -$352.4K | EDGAR |
| 2025-12-30 | ALHC | Sell (S) | −12,694 | -$237.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.